Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, 2020 at 9:30 a.m. EDT.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago^®/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, the United Arab Emirates and Japan, and is commercialized by Newron's Partner Zambon. US WorldMeds currently holds the commercialization rights in the USA and has entered into a definitive agreement to sell its Xadago rights, along with other CNS assets, to Supernus Pharmaceuticals. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com